ATEMNKENG DIBAKI: Open Payments
NPI 1750758512 · CEDAR HILL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,092 in 106 payments from 13 companies in 2025. Trend: 2023 $1,925 · 2024 $1,621 · 2025 $2,092
Food & beverage: $2,079Education: $13
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 21 | $546 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $287 |
| Otsuka America Pharmaceutical, Inc. | 14 | $248 |
| Supernus Pharmaceuticals, Inc. | 21 | $200 |
| E.R. Squibb & Sons, L.L.C. | 10 | $178 |
| Alkermes, Inc. | 9 | $176 |
| Neurocrine BioSciences, Inc. | 7 | $169 |
| Axsome Therapeutics, Inc. | 5 | $91 |
| ABBVIE INC. | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
Products named: INVEGA SUSTENNA, CAPLYTA, Qelbree, SPRAVATO, COBENFY, INGREZZA, ARISTADA, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
